Skip to main content
. 2021 Jun;79(6):736–746. doi: 10.1016/j.eururo.2021.01.017

Fig. 3.

Fig. 3

CD38 expression on prostate cancer epithelial cells and benign epithelial cells. (A) Representative immunofluorescence image showing CD38 expression in benign prostatic epithelium (× 200 magnification, scale bar 100 µm). (B) Representative images showing CD38 expression in prostate cancer epithelial cells. Top row shows examples of CD38+ tumours and bottom row shows CD38− tumours (200× magnification, scale bar 50 µm). (C) CD38 expression was more frequent on benign prostatic epithelial cells (35.8%) than on malignant epithelial cells (7.7%). Fisher’s exact test, p < 0.001. (D) Tumour epithelial cell CD38 expression was more frequent in CSPC biopsies (9.8%; 5/51) than in CRPC biopsies (3.9%; 2/51). McNemar’s test, p = 0.45, not significant. BMT = bone marrow trephine; CRPC = castration-resistant prostate cancer; CSPC = castration-sensitive prostate cancer; LN = lymph node; mCRPC = metastatic castration-resistant prostate cancer; Prostate Bx = prostate biopsy.